DEFA14A: NovaBay Pharmaceuticals Faces Setback: Stockholders Reject Liquidation Plan, Company to Seek Approval Again

NovaBay Pharmaceuticals' stockholders did not approve the proposed liquidation and dissolution plan at a special meeting, prompting the company to schedule another vote.

Summary

• NovaBay Pharmaceuticals held a special meeting on January 30, 2025, to vote on a proposal for liquidation and dissolution, but the proposal was not approved by stockholders.
• Approximately 49% of outstanding shares voted in favor, falling short of the required majority of greater than 50%.
• The company had previously sold its eyecare products and wound care trademarks.
• Despite the failed vote, the Board of Directors believes liquidation and dissolution is still the best option to maximize value for stockholders.
• NovaBay intends to hold a new special meeting to seek stockholder approval for liquidation and dissolution.
• If approved, the company plans to file a Certificate of Dissolution with the Secretary of State of Delaware and proceed with liquidation.
• The liquidation process is expected to take a minimum of nine months under Delaware law.
• The company aims to pay creditors, discharge liabilities, and return remaining value to stakeholders.
• Distributions will be made to stockholders based on holdings as of the date the Certificate of Dissolution is filed.
• The Board reserves the right to abandon liquidation even if approved by stockholders if it's no longer in the company's best interest.
• The company will file a new proxy statement with the SEC for the new special meeting.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the failed vote on liquidation, indicating uncertainty and potential losses for investors. The company is pursuing further action, but the outcome is uncertain.

Positives

• The Board of Directors is actively seeking to maximize the remaining value for the Company and its stockholders.
• The Company intends to pay its creditors and discharge its liabilities, as well as return as much value that may remain to stockholders and other stakeholders, including unsecured convertible note holders and warrant holders.

Negatives

• Stockholders rejected the proposal for liquidation and dissolution, creating uncertainty about the company's future.
• The company must hold another special meeting, incurring additional costs and delaying the liquidation process.
• There is no guarantee that the stockholders will approve the liquidation at the new special meeting.
• The Board reserves the right to abandon the liquidation even if approved by stockholders, creating further uncertainty.

Risks

• The company may not receive stockholder approval for liquidation at the new special meeting.
• The Board may abandon the liquidation even if approved by stockholders.
• The liquidation process could be delayed or not filed at all.
• There will be limited ability to sell or transfer Company securities after the Certificate of Dissolution is filed.
• Forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially.

Future Outlook

The company intends to hold a new special meeting of stockholders to obtain approval of the Liquidation and Dissolution. If approved, the company plans to file a Certificate of Dissolution with the Secretary of State of Delaware and proceed with the Liquidation and Dissolution in accordance with the Plan of Dissolution and Delaware law as soon as practical following the new special meeting.

Management Comments

• The Board, upon further analysis of the best opportunity to maximize the remaining value for the Company and its stockholders, among the other alternatives currently available, determined that it is in the best interests of the Company and its stockholders for the Company to continue pursuing the voluntary Liquidation and Dissolution pursuant to the Plan of Dissolution.

Industry Context

Many small pharmaceutical companies explore strategic alternatives, including asset sales and liquidation, when facing financial challenges or limited growth prospects. This announcement reflects NovaBay's attempt to navigate such circumstances.

Comparison to Industry Standards

• It is difficult to compare NovaBay's situation to industry standards without knowing the specifics of their financial condition and the terms of the asset sale.
• However, companies like Valeant (now Bausch Health) and Endo International have faced similar challenges related to debt and declining revenue, leading to asset sales and restructuring efforts.
• The success of NovaBay's liquidation will depend on its ability to efficiently manage the process and maximize the value returned to stakeholders, which is a common goal in such situations.

Stakeholder Impact

• Stockholders may receive distributions from the liquidation, but the amount is uncertain.
• Creditors will be paid to the fullest extent possible.
• Employees have likely been impacted by the asset sales and potential liquidation.
• Warrant holders and unsecured convertible note holders may receive some value.

Next Steps

• File a new proxy statement with the SEC.
• Hold a new special meeting of stockholders to vote on the Liquidation and Dissolution.
• If approved, file a Certificate of Dissolution with the Secretary of State of Delaware.
• Proceed with the Liquidation and Dissolution in accordance with the Plan of Dissolution and Delaware law.

Key Dates

Keywords

Liquidation, Dissolution, Stockholders, NovaBay Pharmaceuticals, Special Meeting, Asset Sale, Delaware Law, Proxy Statement